GHRP-6 vs IGF-1 LR3: What Is the Difference?
One is a piece of pharmacology history that led scientists to discover a hormone nobody knew existed. The other is a growth signal with a specific engineering tweak.
In plain English
GHRP-6 is a six-amino-acid molecule made in the 1980s that triggers growth hormone release. Remarkably, it was built years before anyone identified the receptor it acts on.
IGF-1 LR3 is a modified insulin-like growth factor 1 — a downstream growth signal, altered so carrier proteins cannot capture and hold it.
The difference, without the jargon
GHRP-6 has one of the better stories in pharmacology. It clearly worked, but it acted on a receptor nobody had identified. Tracking down that receptor, and then hunting for the natural molecule that was supposed to fit it, eventually led to the 1999 discovery of ghrelin — a hormone found because a synthetic compound pointed the way. IGF-1 LR3 has no such mystery; it is a deliberate modification of a known growth factor. In the vial they could hardly be less alike. GHRP-6 contains two copies of tryptophan, the amino acid most easily damaged by light, so it demands genuinely strict darkness and will visibly yellow when it degrades. IGF-1 LR3 is a folded protein that needs acidic liquid to dissolve and can be ruined by freezing and thawing without any visible change at all.
Common questions
What is the difference between GHRP-6 and IGF-1 LR3?
GHRP-6 prompts the release of growth hormone by acting on a receptor in the body. IGF-1 LR3 is a modified version of a growth signal that appears downstream of growth hormone. One triggers a system; the other is a component of it.
How did GHRP-6 lead to the discovery of ghrelin?
GHRP-6 worked on a receptor that had not been identified. Researchers cloned that receptor in 1996, then searched for the natural molecule meant to activate it. That search ended in 1999 with ghrelin — a previously unknown hormone found because a synthetic compound led scientists to it.
Why does GHRP-6 turn yellow?
Yellowing is light damage to its two tryptophan residues becoming visible. Tryptophan is the amino acid most vulnerable to light, and GHRP-6 has two of them, so strict light protection is a real requirement and discolouration is a reason to discard the vial.
Technical reference below
How they actually differ
Comparing the two: GHRP-6 is synthetic hexapeptide, met-enkephalin analogue and ghrelin-receptor agonist, while IGF-1 LR3 is recombinant 83-residue protein analogue of igf-1 — different molecular classes with different handling consequences; they call for different primary diluents (sterile or bacteriostatic water versus dilute acetic acid (0.1 m) or 10 mm hcl — required for initial dissolution); their leading degradation routes differ (tryptophan photo-oxidation at two independent positions for GHRP-6, denaturation and aggregation for IGF-1 LR3), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
GHRP-6 — origin
GHRP-6 was among the first synthetic growth hormone secretagogues, developed from met-enkephalin analogues in the 1980s — years before the ghrelin receptor it acts on was even identified. It is a genuine piece of pharmacological history: the compound was found first and its target second, and that search for the endogenous ligand of its receptor eventually led to the discovery of ghrelin in 1999.
IGF-1 LR3 — origin
IGF-1 LR3 is an engineered analogue carrying two changes to native IGF-1: an arginine substitution at position 3 and a 13-residue N-terminal extension. The Arg3 substitution is the functional one — it drastically reduces binding to IGF binding proteins, which normally sequester the great majority of circulating IGF-1. The result is a molecule that stays free rather than bound.
GHRP-6 research themes
Acts at GHS-R1a — the receptor whose search for an endogenous ligand led to ghrelin's discovery.
Strong GH-releasing activity in research models, historically the compound's defining property.
Ghrelin-receptor activity links it to appetite pathways in metabolic research models.
A landmark in reverse pharmacology: the synthetic ligand preceded knowledge of both receptor and natural ligand.
IGF-1 LR3 research themes
The Arg3 substitution reduces binding-protein affinity, which is the entire design rationale.
Widely used in cell-culture research as a growth-factor supplement.
Studied in muscle-biology research models.
The canonical downstream pathway examined in IGF-1 receptor research.
GHRP-6 handling
- Amber vials or foil wrapping should be treated as required, not optional.
- Reconstitute under reduced lighting where practical.
- Avoid contact with trace metals, which catalyse oxidative degradation of aromatic residues.
IGF-1 LR3 handling
- Dissolve in dilute acetic acid or dilute HCl FIRST; do not attempt direct dissolution in water or PBS.
- Add carrier protein (e.g. 0.1% BSA) for storage of dilute solutions to prevent adsorptive loss.
- Prepare single-use aliquots — freeze–thaw denaturation is irreversible.
- Do not vortex; agitation denatures folded proteins at the air–liquid interface.
Both third-party tested
Every Popular Peptides batch of GHRP-6 and IGF-1 LR3 is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
GHRP-6 reference
Related comparisons
GHRP-6 and IGF-1 LR3 are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.